Nilotinib induces deeper molecular responses vs continued imatinib in patients with ph+ chronic myeloid leukemia (CML) with detectable disease after ≥ 2 years on imatinib: ENESTcmr 12-months results

---

Autoria(s): Cervantes, C.; Hughes, T.; Etienne, G.; De Souza, C.A.; Dorlhiac Llacer, P.E.; Schwarer, A.; Leber, B.; Lipton, J.; Spector, N.; Reynolds, J.; Collins, L.; Szczudlo, T.; Rea, D.

Data(s)	01/06/2012
Identificador	http://hdl.handle.net/10536/DRO/DU:30060095
Idioma(s)	eng
Publicador	Ferrata Storti Foundation
Relação	http://dro.deakin.edu.au/eserv/DU:30060095/reynolds-nilotinibinduces-2012.pdf http://www.haematologica.org/content/97/supplement_1.toc
Palavras-Chave	#BCR-ABL #chronic myeloid leukemia #molecular remission #molecular response
Tipo	Journal Article